<DOC>
	<DOCNO>NCT01187615</DOCNO>
	<brief_summary>This multi-center , open-label , non-randomized Phase I study define safety profile , maximum tolerate dose ( MTD ) potential pharmacokinetic interaction regorafenib combination pemetrexed cisplatin patient Stage IIIB Stage IV nonsquamous Non-Small Cell Lung Cancer ( NSCLC ) determine impact combine administration pharmacokinetics regorafenib , pemetrexed , cisplatin . In Part A trial , regorafenib administer sequential dose seven day wash period next infusion pemetrexed cisplatin . Regorafenib administer dose 160 mg qd Day 2 Day 14 follow 7 day break . In Part B trial , regorafenib administer continuously Day 1 Day 21 . Only Cycle 1 , regorafenib dose start Day 2 order ass pharmacokinetics pemetrexed cisplatin without concomitant regorafenib dosing .</brief_summary>
	<brief_title>Determination Safety , Efficacy , Pharmacokinetics `` Regorafenib '' Combined With Pemetrexed Cisplatin Patients With Nonsquamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Age &gt; = 18 year . Histological cytological diagnosis metastatic Stage IV locally advance , unresectable confirm Stage IIIB nonsquamous NonSmall Cell Lung Cancer ( NSCLC ) amenable local therapy curative intent . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 Life expectancy least 12 week . Adequate bone marrow , liver , renal function Controlled blood pressure [ define systolic Blood Pressure ( BP ) &lt; =150 mmHg diastolic Blood Pressure ( BP ) &lt; = 90 mmHg ] Men woman childbearing potential enrol study must use adequate barrier birth control measure course study Sensory neuropathy sensory alteration paresthesia ( include tingle ) , interfere function Hearing impairment Persistent proteinuria Common Toxicity Criteria ( CTC ) Grade 3 high Cardiac disease : congestive heart failure &gt; New York Heart Association ( NYHA ) Class II ; patient must unstable angina ( anginal symptom rest ) newonset angina ( begin within last 3 month ) myocardial infarction within past 6 month ; cardiac ventricular arrhythmia require antiarrhythmic therapy Brain metastasis : patient neurological symptom undergo Computerized Tomography ( CT ) scan / Magnetic Resonance Imaging ( MRI ) brain exclude new progressive brain metastasis . Patients brain metastasis exclude trial Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study medication Pulmonary hemorrhage/bleeding event &gt; Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 within 4 week prior start study treatment . Clinically significant hemoptysis ( 1 teaspoon ) past 3 month Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week prior start study treatment Evidence history bleed diathesis coagulopathy Centrally locate tumor radiologic evidence ( CT MRI ) local invasion major blood vessel The effect third space fluid , pleural effusion ascites , pemetrexed unknown . In patient clinically significant third space fluid , consideration give drain effusion prior study start Patients phaeochromocytoma Excluded Therapies Medications , Previous Concomitant Prior treatment systemic chemotherapy metastatic NSCLC . Patients underwent prior systemic treatment radiotherapy NSCLC neoadjuvant adjuvant set eligible , chemotherapy treatment within last 6 month prior study entry allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Nonsquamous Non-small cell lung cancer</keyword>
	<keyword>Phase I</keyword>
</DOC>